RxDoctor Payments Data

Frances Marrero Barrera, MD

Cornea and External Diseases Specialist · Caguas, PRNPI 1275049488

Payments from drug & device makers

$2,256in general payments, 2019–2025

Across 33 payments — averaging $68.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$768
  • Mallinckrodt Hospital Products Inc.$453
  • Alcon Puerto Rico Inc$321
  • AbbVie$187
  • Glaukos Corporation$149
  • Amgen$115
  • plus $262 from 5 others

What the payments were for

  • Food & beverage$2,14695%
  • Education$1095%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$23,235
Medicare patients
41
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine107$45,389
Prednisolone Acetate795$38,890
Fluorometholone319$22,697
XiidraLifitegrast25$17,787
Cyclosporine114$17,539
LumiganBimatoprost48$14,197
Ofloxacin470$10,439
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat175$5,659
Latanoprost337$4,175
CombiganBrimonidine Tartrate/Timolol19$4,010
Doxycycline Monohydrate78$3,746
Alphagan PBrimonidine Tartrate17$3,344
ValacyclovirValacyclovir Hcl52$3,231
Ketorolac Tromethamine84$3,064
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$1,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$187$66,940191 claims
Bausch & Lomb Americas Inc.Xiidra$768$17,78725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in Caguas

Where these figures come from

Is this you, or does something look wrong? →